The National Advisory Committee on Immunization (NACI) has issued new advice to the federal, provincial, and territorial governments on the recommended use of the Pfizer-BioNTech COVID-19 vaccine in adolescents 12 to 15 years of age. NACI previously issued advice on the use of this vaccine in adolescents 16 to 18 years of age when it was authorized for this age group in December 2020.
On May 5, 2021, Health Canada authorized the use of the Pfizer-BioNTech COVID-19 mRNA vaccine in adolescents 12 to 15 years of age, following the results of a Phase 3 clinical trial in this population.
NACI recommends that a complete series with the Pfizer-BioNTech COVID-19 vaccine should be offered to individuals 12 to 18 years of age who can receive the vaccine.
- Recommendation
- Americas
- Canada
- Pfizer-BioNTech vaccine
- adolescents
